How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


A plasma protein marker panel for diagnosis of colorectal cancer

Organization name

DKFZ Deutsches Krebsforschungszentrum



Sigmoidoscopy and colonoscopy, the current goldstandards for detection of CRC in the distal andtotal colorectum, respectively, are limited by several disadvantages, such as high costs, limited resources and poor compliance. So other costeffective and sensitive methods for the early detection of colorectal cancer are urgently needed and very important from the health economic standpoint. The invention offers a plasma protein biomarker set that can be used as a diagnostictool for diagnosis and stratification of colorectal cancer.

The Technology and Development Stage

Based on the prospective BliTz study from 2005–2012 including approximately 5500 participants a panel of 17 plasma proteins was identified by analysis of 35 CRC patients who were compared to a representative sample of 54 controls free of colorectal neoplasms. This set was further reduced to a core panel of 8 proteins without substantial loss of predictive power.

Applications and Commercial Opportunity

DKFZ is looking for a commercial partner for further development of the marker panel alone or in combination with other markers towards clinical application.


The investigators and inventors are: Chen Hongda and Hermann Brenner, both of DKFZ.

Intellectual Property

A priority patent application “Biomarker panel for diagnosing cancer” EP15161465.8 has been filed at the Europe Patent Office March 27, 2015. A subsequent international patent application was filed March 27, 2016 as PCT/EP2016/056314.

Further Information

No further public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).

For further information, including a CDA, please contact:

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback to "A plasma protein marker panel for diagnosis of colorectal cancer"


latest entries

latest entries